Angiogenesis - Where do we stand now?

Therapeutic modulation of angiogenesis is still in its infancy, but the baby is showing considerable potential. The ultimate success of this therapeutic modality will depend on careful translational research program that will incorporate the ever-evolving basic understanding of the biology of angiogenesis into an effective clinical trials program. The likely keys include the careful choice of a biological agent that may be different for different indications, effective delivery modality with pharmacokinetic properties matching biological needs, and the meticulous choice of patient population and end points for study. © 2005 American Heart Association, Inc.